Brief: Alpha Cognition Signs $44 Million Exclusive Licensing Agreement For Zunveyl In China
08/01/2025 14:24
Jan 8 (Reuters) - Alpha Cognition Inc ACOG.O :
* ALPHA COGNITION ANNOUNCES A $44 MILLION EXCLUSIVE
LICENSING
AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ZUNVEYL
(BENZGALANTAMINE), AN FDA-APPROVED TREATMENT FOR
MILD-TO-MODERATE ALZHEIMER’S DISEASE, IN CHINA
Source text: urn:newsml:reuters.com:*:nBw7FfyWza
Further company coverage: ACOG.O
((Reuters.Briefs@thomsonreuters.com;))